ecteinascidin 743 has been researched along with Cancer of Kidney in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Badalamenti, G; Bello, E; Casali, PG; Collini, P; Colombo, C; Cominetti, D; D'Incalci, M; Dagrada, GP; Dei Tos, AP; Frapolli, R; Gronchi, A; Morosi, C; Negri, T; Pilotti, S; Provenzano, S; Renne, SL; Saponara, M; Stacchiotti, S; Tortoreto, M; Vincenzi, B; Zaffaroni, N; Zuco, V | 1 |
Beijnen, JH; Beumer, JH; Lopez-Lazaro, L; Rademaker-Lakhai, JM; Rosing, H; Schellens, JH | 1 |
1 trial(s) available for ecteinascidin 743 and Cancer of Kidney
Article | Year |
---|---|
Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Dioxoles; Feces; Female; Half-Life; Humans; Isoquinolines; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Sarcoma; Sarcoma, Synovial; Tetrahydroisoquinolines; Trabectedin | 2005 |
1 other study(ies) available for ecteinascidin 743 and Cancer of Kidney
Article | Year |
---|---|
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cerebellar Neoplasms; Dacarbazine; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Furans; Humans; Ifosfamide; Ketones; Kidney Neoplasms; Male; Meningeal Neoplasms; Mice, SCID; Middle Aged; Pleural Neoplasms; Response Evaluation Criteria in Solid Tumors; Retroperitoneal Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Solitary Fibrous Tumors; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2017 |